tiprankstipranks
Trending News
More News >

BlackRock Increases Stake in MaxCyte to 9.98%

Story Highlights
BlackRock Increases Stake in MaxCyte to 9.98%

Confident Investing Starts Here:

MaxCyte ( (MXCT) ) has issued an announcement.

MaxCyte, Inc. announced a change in its major holdings, with BlackRock, Inc. increasing its voting rights in the company to 9.98%. This adjustment in BlackRock’s stake could potentially influence MaxCyte’s strategic decisions and market positioning, reflecting confidence from a significant institutional investor.

More about MaxCyte

MaxCyte, Inc. operates in the biotechnology industry, focusing on cell-based therapies and providing cell-engineering platforms. The company is known for its proprietary flow electroporation technology, which is used in the development of advanced medicines.

Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App